HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Kevin O Hicks Selected Research

tirapazamine (SR 4233)

1/2013Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
3/2012The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
10/2010Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
12/2007Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
12/2007Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
10/2007Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
7/2007Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
8/2006Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
2/2005Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
6/2004Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Kevin O Hicks Research Topics

Disease

16Neoplasms (Cancer)
12/2014 - 03/2002
15Anoxia (Hypoxia)
04/2014 - 08/2006
2Carcinoma (Carcinomatosis)
02/2005 - 06/2004
1Colonic Neoplasms (Colon Cancer)
08/2006

Drug/Important Bio-Agent (IBA)

11tirapazamine (SR 4233)IBA
01/2013 - 09/2003
9OxygenIBA
12/2014 - 06/2004
5ProdrugsIBA
01/2013 - 06/2007
5PR-104AIBA
01/2013 - 07/2007
4PR-104IBA
01/2013 - 07/2007
2CytotoxinsIBA
04/2014 - 11/2008
2OxidoreductasesIBA
01/2013 - 03/2012
2Green S (green 5)IBA
01/2013 - 01/2013
14-nitroimidazoleIBA
04/2014
1azomycinIBA
04/2014
1SulfonamidesIBA
04/2014
1Glucose (Dextrose)FDA LinkGeneric
01/2014
1TH 302IBA
01/2013
1Nitro CompoundsIBA
01/2013
1OxidesIBA
01/2013
12- (2- nitro- 1H- imidazol- 1- yl)- N- (2,2,3,3,3- pentafluoropropyl)acetamideIBA
03/2012
1NitrogenIBA
11/2008
1HydrogenIBA
12/2007
1Mechlorethamine (Nitrogen Mustard)FDA Link
07/2007
1DNA (Deoxyribonucleic Acid)IBA
07/2007
1docetaxel (Taxotere)FDA Link
07/2007
1Hydroxylamine (Hydroxylamine Hydrochloride)IBA
07/2007
1nitromide (Unistat)IBA
07/2007
1gemcitabineFDA Link
07/2007
1NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA
06/2007
1Carbon MonoxideIBA
06/2007
13-amino-1,2,4-benzotriazine-1-oxideIBA
06/2004
1SuspensionsIBA
06/2004
15-(1-aziridinyl)-2,4-dinitrobenzamideIBA
03/2002

Therapy/Procedure

8Heterologous Transplantation (Xenotransplantation)
01/2013 - 03/2002
4Radiotherapy
01/2014 - 07/2007
3Aftercare (After-Treatment)
10/2007 - 08/2006
1Intravenous Infusions
12/2014
1Drug Therapy (Chemotherapy)
07/2007